Ryan Scott

Dr. Hyman Muss explains why older patients with breast cancer face distinct physical, cognitive and emotional challenges that require tailored treatment plans. It is vital that clinicians, caregivers and patients themselves be aware of the unique challenges that are often […]

Treatment with a custom-made vaccine and immune checkpoint inhibitor safely triggered a strong immune response in patients with bladder cancer, showing potential for wider use. Treatment with an immune checkpoint inhibitor in combination with the PGV001 vaccine, a custom-made vaccine,

Investigators are using MET immunohistochemistry testing to address unmet needs in NSCLC treatment: © stock.adobe.com. Caris Life Sciences is aiming to provide MET immunohistochemistry testing as a standard of care for all patients with non-squamous non-small cell lung cancer, according

An expert reflects on the treatment landscape of Waldenström macroglobulinemia, emphasizing diagnostics, collaboration and managing neuropathy effectively. The management of Waldenström macroglobulinemia (WM), a rare form of blood cancer, requires a nuanced approach with up-to-date treatments and the collaborative treatment

Cemsidomide led to strong responses at multiple doses in patients with multiple myeloma, including one complete response with no minimal residual disease detected. Treatment with cemsidomide resulted in notable responses at multiple dose levels, showing potential for a best-in-class profile,

Dr. Daniel J. Boffa discusses the link between smoking cessation and improved survival rates for people diagnosed with cancer who are active smokers. Although one in five cancer diagnoses are linked to smoking, approximately 12% of individuals in the United

Dr. Kara Kelly highlights diagnostic delays, treatment gaps and late effects faced by adolescents and young adults with lymphoma. Adolescent and young adult (AYA) patients with cancer, specifically lymphoma — a type of blood cancer — face many unique challenges

Personalized treatment for older adults with breast cancer should consider functional status, comorbidities and support systems — not just chronological age. When treating older patients with breast cancer, it is important to understand that there are many unique aspects that

The first site has opened for the OVATION 3 study testing IMNN-001 in women newly diagnosed with advanced ovarian cancer. The first trial site has been initiated for a phase 3 pivotal study entitled OVATION 3, which will investigate IMNN-001

Elraglusib plus gemcitabine and nab-paclitaxel significantly improved survival as a first-line treatment for metastatic pancreatic cancer in a global phase 2 trial. Eraglusib in combination with gemcitabine and nab-paclitaxel achieved statistical significance in the first-line treatment of metastatic pancreatic ductal